Previous 10 | Next 10 |
2024-01-22 10:00:11 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-18 07:24:27 ET More on NovoCure, Zai Lab, etc. Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade) NovoCure: Significant Upside Even Without A Breakthrough Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript Novocure reports better-tha...
Phase 1/2 TRIDENT-1 study data demonstrate repotrectinib’s clinically meaningful response rates and durable clinical activity in patients with ROS1-positive non-small cell lung cancer Data show robust intracranial activity both in TKI naïve and pretreated settings in patients ...
2023-12-30 05:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-27 14:59:02 ET More on NovoCure NovoCure: Significant Upside Even Without A Breakthrough NovoCure Limited 2023 Q3 - Results - Earnings Call Presentation NovoCure Limited (NVCR) Q3 2023 Earnings Call Transcript Novocure to eliminate 13% of workforce in...
2023-12-21 08:16:36 ET Losers: Polished.com ( POL ) -36% . Dune Acquisition Corporation ( DUNE ) -17% . Panbela Therapeutics ( PBLA ) -10% . Applied UV ( AUVI ) -9% . Tantech Holdings Ltd ( TANH ) -9% . Longeveron ( LGVN ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024: J.P. Morgan 42nd Annual Healthcare Conference Presentation: Monday, January 8, 2024, 3:45 p.m. PS...
BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced that China’s National Healt...
2023-12-13 08:23:33 ET More on Zai Lab Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade) Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript Zai Lab Q3 2023 Earnings Preview Seagen, Genmab update Phase 3 data for uterine cancer therapy ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART ® (efgarti...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...